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Considerable progress has been made in breast cancer treatment in Europe over the past three decades,
yet survival rates for metastatic disease remain poor, underlining the need for further advances. While
the use of predictive biomarkers for response to systemic therapy could improve drug development
efﬁciency, progress in identifying such markers has been slow. The currently inadequate classiﬁcation of
breast cancer subtypes is a further challenge. Improved understanding of the molecular pathology of the
disease has led to the identiﬁcation of new targets for drug treatment, and evolving classiﬁcations should
reﬂect these developments. Further ongoing challenges include difﬁculties in ﬁnding optimal combi-
nations and sequences of systemic therapies, circumventing multidrug resistance and intra-tumor het-
erogeneity, problems associated with fragmentation in clinical trials and translational research efforts.
Adoption of some of the strategies identiﬁed in this article may lead to further improvements in out-
comes for patients with the disease.
© 2015 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Breast cancer is the most common cancer inwomenworldwide,
being responsible for over 500,000 deaths in 2004 [1]. The disease
places a considerable burden on patients and healthcare systems,
accounting for 10% of overall cancer costs in the European Union
[2]. Nevertheless, progress has been made in the treatment of
breast cancer in the Western world over the past three decades,
with age-standardized, 5-year relative survival rates in Europe
increasing from 73% to 83% between 1992 and 2008 [3]. Despite
these advances, 5-year relative survival rates for metastatic disease
remain poor [4], though the modest improvements in prognosis
observed with the advent of modern systemic treatments suggest
that more progress could be made as a result of new therapeuticHospital of Prato, Istituto
4766; fax: þ39 0574 29798.
Ltd. This is an open access article uapproaches [5e7]. Nonetheless, survival rates for the disease in
Europe still lag behind those observed in the United States [8],
underlining the need for further advances across the region.
One of the problems facing the medical treatment of breast
cancer in Europe is the high cost in the current economic climate.
While the use of predictive biomarkers for response to systemic
therapy could improve treatment efﬁcacy and reduce costs, prog-
ress in identifying such markers has been slow. Additional chal-
lenges include the difﬁculty in ﬁnding optimal combinations,
sequencing of chemotherapy and biologic therapy, circumventing
multidrug resistance and intra-tumor heterogeneity, along with
problems associated with disconnects between clinical trials and
translational research efforts.
Breast cancer subtypes: evolving deﬁnitions and clinical
relevance
Invasive breast carcinoma has traditionally been classiﬁed ac-
cording to histomorphologic features into several variants, thender the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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ductal carcinoma in situ [DCIS] and lobular in situ neoplasia,
respectively) [9]. Such histologic classiﬁcations are currently used
in clinical practice along with determination of TNM stage (Tumor
size, Nodal involvement, presence of Metastases) to make pre-
dictions of disease prognosis [10,11], though they have limited
usefulness when selecting the best systemic therapies. More
recently, it has become clear that breast tumors are highly het-
erogeneous in their molecular composition [12], with different
subtypes varying in their characteristics and natural history
[13e16]. Measurement of these molecular subtypes, which in-
cludes determination of estrogen receptor (ER), progesterone re-
ceptor (PgR) and human epidermal growth factor receptor 2 (HER2)
status, and sometimes also the proliferation marker Ki-67, is
important since such factors can assist in the estimation of both
disease recurrence risk and response to therapy [9]. Receptor status
also has an impact on survival, with triple (ER/PgR/HER2) negative
breast cancer (TNBC) being associated with the poorest outcome
(Table 1) [17].
Breast cancer subtypes can be deﬁned by the use of gene
expression microarrays such as Affymetrix GeneChip (Affymetrix,
Santa Clara, USA) [18,19] or Illumina (Illumina Inc., San Diego, USA)
[20], or by clinical use of gene expression to direct therapeutic
decisions: Mammaprint [21], Oncotype DX (Genomic Health
Inc., USA) [22], or PAM50 [23]. However, such methods are not
commonly undertaken at present due to cost and limited avail-
ability, so a simpliﬁed approximation to this classiﬁcation using
clinicopathologic determination of ER, PgR and HER2 is often used
to help guide treatment selection in clinical practice [24,25]. Such
clinicopathologic criteria involve the use of immunohistochemistry
(IHC) to assess receptor status and score protein levels semi-
quantitatively, while HER2/neu gene ampliﬁcation is evaluated by
ﬂuorescent in situ hybridization (FISH). However, use of IHC is not
without problems, with quality assurance for interpretation of the
results and quantiﬁcation being particularly challenging [26].
Indeed, such issues have led to sizeable discrepancies between
centers in the results of receptor measurements according to cen-
tral pathology review. As assessment by IHC is now the predomi-
nant determinant of treatment for breast cancer, accurate
determination of receptor status is crucial since false negatives/
positives have an impact on disease management [26]. Conse-
quently, the precise cut-off points for receptor measurement in
clinical trials should be considered with care, with protocols
following guidelines for the determination of ER, PgR and HER2
[27,28]. Measurement of Ki-67 may be used in order to differentiate
between luminal A and B breast cancer and to identify candidates
for chemotherapy. Use of Ki-67 measurement remains controver-
sial due to the wide variations in analytical methods employed andTable 1
Breast cancer receptor subtypes and associated 5-year survival rates. Reprod
Characteristic Overall survival, %
Subtype
ER/PgRþ, HER2 (luminal A) 90.3% (87.6e92.5
ER/PgRþ, HER2þ (luminal B) 88.7% (79.2e94.1
ER/PgR, HER2þ 78.8% (66.0e87.7
ER/PgR, HER2 79.0% (70.8e85.3
ER/PgR status
ER/PgRþ 90.1% (87.5e92.2
ER/PgR 79.0% (72.4e84.4
HER2 status
Positive 84.6% (77.3e89.9
Negative 88.5% (85.9e90.6
Overall 87.8% (85.4e89.9
CI, conﬁdence interval; ER, estrogen receptor; HER2, human epidermal growlack of quality control; however, such variability is expected to
decrease following recent recommendations on pre-analytical and
analytical assessment of this marker [29]. Epidermal growth factor
receptor (EGFR), cytokeratin (CK) 5/6 expression and other markers
can also be measured in order to determine basal subtype in pa-
tients with TNBC [25].
Although breast cancer subtypes deﬁned by clinicopathologic
criteria are similar to intrinsic subtypes identiﬁed by gene expres-
sion proﬁling and represent a useful surrogate deﬁnition, they are
not identical. Furthermore, this classiﬁcation of breast cancer sub-
types remains suboptimal as a means of directing therapeutic de-
cisions since substantial heterogeneity exists within each
molecular subtype, leading to considerable variability in response
to therapy. However, it is hoped that molecular subtyping using
gene expression proﬁling will become routine practice after 2015,
should the large trials TAILORx (Trial Assigning IndividuaLized
Options for Treatment [Rx]) and MINDACT (Microarray In Node
negative Disease may Avoid ChemoTherapy) release ‘positive’ re-
sults, namely that low proliferative luminal cancers can be safely
treated with endocrine therapy only. Gene expression proﬁling has
already been endorsed by the latest St Gallen International Breast
Cancer Consensus Conference (2013) for making adjuvant therapy
decisions [30].
Current treatment options and unmet needs in breast cancer
Multidisciplinary team (MDT) meetings, involving oncologists,
surgeons, radiologists, nurses and pathologists, are considered
ideal for the management of early breast cancer so that diagnostic
and treatment aspects of patient care can be discussed. Indeed,
regular MDT meetings are common in Europe, particularly for
complex cases, with treatment recommendations being based on
national or European guidelines [25,31].
Treatment for breast cancer is dependent on disease stage,
histologic andmolecular subtypes andmenopausal status. Further
aspects inﬂuencing treatment choice for early breast cancer
include balancing the risk of relapse with the beneﬁt of inter-
vention and patient factors such as the impact of treatment on
fertility. Surgery (mastectomy or breast-conserving surgery with
or without lymph node dissection) and radiotherapy play an
important role in early breast cancer: systemic therapy may be
used for almost all women and is the predominant treatment for
those with advanced disease [25,32]. Tamoxifen, with or without
ovarian function suppression, is recommended for premeno-
pausal women with hormone-sensitive (ERþ) disease and an
aromatase inhibitor (AI) is the preferred option for post-
menopausal women. AI therapy can be induced upfront or
sequentially by switching from tamoxifen to AI and vice versauced with permission from Onitilo et al. 2009 [17].
(95% CI) Disease-free survival, % (95% CI)
) 86.8% (83.8e89.4)
) 83.2% (74.0e89.6)
) 66.0% (53.9e76.3)
) 73.5% (65.0e80.5)
) 86.4% (83.6e88.8)
) 70.8% (63.9e76.8)
) 75.9% (68.6e81.9)
) 84.7% (81.9e87.2)
) 83.1% (80.5e85.5)
th factor receptor; PgR, progesterone receptor.
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therapy after 5 years of tamoxifen has also been shown to prolong
disease-free survival in postmenopausal women with early breast
cancer [34], with the greatest beneﬁt seen in those who were
premenopausal at the time of diagnosis but postmenopausal
following completion of tamoxifen [30,35]. Nevertheless, the
adverse effects of AIs must be considered carefully, particularly in
those with pre-existing ischemic cardiac disease [30,36,37].
Neoadjuvant endocrine therapy with an AI or tamoxifen may
facilitate tumor shrinkage to allow breast conservation in post-
menopausal women with highly endocrine-responsive disease,
and 1-year adjuvant treatment with an anti-HER2 agent (e.g.
trastuzumab) is advocated for patients with HER2þ disease in
addition to chemotherapy [25]. The patient groups that beneﬁt
from chemotherapy are not well deﬁned and biomarkers for
response are lacking. Nevertheless, indications for treatment
include breast cancer of high histologic grade, high levels of
proliferation (determined by Ki-67 measurement), low hormone
receptor status, HER2þ status and the presence of TNBC.
Anthracyclines and taxanes are the preferred chemotherapeutic
agents, though no single standard of care exists [25]. Patients with
luminal A breast cancer do not respond well to chemotherapy;
consequently, such treatment has lost popularity for this subtype
but remains in use in the presence of a high tumor burden (e.g. at
least four positive nodes). While patients with luminal B breast
cancer can respond to chemotherapy, the optimal treatment is
uncertain and improved ways of identifying those who will
beneﬁt are required. No single treatment algorithm can be deﬁned
for patients with advanced disease due primarily to the lack of
biologically driven, predictive markers of treatment activity.
Consequently, treatment selection must be made according to
individual circumstances, taking into account a number of factors
including response to previous treatments, disease-free interval,
tumor burden, biomarker expression, presence/absence of
symptoms, clinical trial availability and patient preference. Ther-
apeutic goals for those with advanced disease include disease
control, preservation or improvement in quality of life and pro-
longation of survival, with symptom palliation and end of life care
advocated for those with end-stage disease [38].
Despite the considerable progress made in the treatment of
breast cancer in recent years, challenges still remain. In particular,
for patients with early disease, there is a signiﬁcant need for new
targeted agents alongwith novel ways of identifying thosewhowill
beneﬁt from them, especially for individuals with luminal B breast
cancer and TNBC. Indeed, management of patients with these tu-
mor subtypes is one of the major issues in breast cancer and
improved understanding of drivers and poor prognostic groups are
needed. Unmet needs in HER2þ breast cancer include treatment of
trastuzumab-resistant disease and prediction of the subpopulation
that will beneﬁt from costly dual targeting interventions, such as
the combination of trastuzumab and pertuzumab.
Challenges in advanced breast cancer include the need for bio-
logically driven criteria to guide treatment choice, identiﬁcation of
the optimal combinations or sequences of targeted agents and
integration of new agents into current regimens. In addition, the
optimal duration of anti-HER2 therapy for patients with HER2þ
breast cancer remains under active investigation in the adjuvant
setting. Further research is also needed into the appropriate means
of monitoring disease progression, though incorporation of imag-
ing into clinical trials and the development of circulating markers
(including circulating tumor DNA [ctDNA]) may help in this regard.
The cost of long-term treatment for patients with advanced breast
cancer is also a pressing concern for the future, since welcome
recent advances in therapy mean that such patients may receive
treatment for a considerable length of time.Challenges in new drug development in breast cancer and the
importance of biomarkers
The development of new drugs for breast cancer is hindered
by high cost, low likelihood of success due to high attrition rates
and poor understanding of the subpopulations that beneﬁt from
their use [39]. Despite almost 100,000 patients being enrolled in
clinical trials with taxane-based regimens, progress in the
knowledge of which patients beneﬁt from such treatment has
been minimal and no biomarkers for response or resistance have
been validated. Biomarkers for targeted therapy are similarly
lacking and available data are conﬂicting. Of particular concern is
the fact that no single marker, beyond HER2, has been able so far
to robustly identify patients unlikely to beneﬁt from anti-HER2
therapies.
There is a need for novel trial designs to be adopted in order to
hasten drug development for breast cancer in patient subgroups
likely to derive substantial beneﬁts. One such approach is the pre-
operative ‘window of opportunity’ trial [40] in which patients
receive the investigational drug before surgery, with biopsies taken
before the drug is given and prior to surgery. Such trials recruit
patients faster than neoadjuvant trials, involve less than 150 in-
dividuals and can be used to assess whether a targeted agent affects
the putative target in humans. However, recruitment into such
trials can be an issue since there may be little direct beneﬁt for the
patients enrolled; patients may also be deterred by additional bi-
opsies or the potential risk of troublesome side-effects. Neo-
adjuvant trials are also useful to establish a proof of concept for new
drugs, and can help inform the decision as to whether to pursue
development in the adjuvant setting; safety should be a primary
consideration for these trials as the patient population is poten-
tially curable, with particular care being required for anti-vascular
endothelial growth factor drugs to avoid wound healing issues af-
ter surgery. The post-neoadjuvant setting is also attractive; here,
one would randomize patients with residual disease after neo-
adjuvant chemotherapy to receive the investigational agent in
addition to standard of care, namely endocrine treatment (for pa-
tients with luminal B breast cancer), or trastuzumab (for those with
HER2þ breast cancer) or placebo for individuals with TNBC (as
there is no clear standard of care in this setting) versus standard of
care alone. These trials do not need to be large, since they focus on
‘high-risk’ populations.
At present, registration authorities favor demonstration of an
overall survival (OS) advantage in clinical trials. However, OS can be
a challenging endpoint, particularly in studies employing crossover
from standard therapy to the new therapy (which reﬂects clinical
practice). Indeed, use of OS as a mandatory endpoint for advanced
breast cancer registration trials may lead to a lack of new ﬁrst- or
second-line treatment options for patients with metastatic disease;
therefore, alternative endpoints are needed. While some trials
employ quality of life as a surrogate endpoint [41], the question-
naires used may not accurately reﬂect patients' daily life. One
endpoint that has utility as a surrogate for long-term outcome,
particularly for neoadjuvant trials in patients with ERe breast
cancer, is pathologic complete response (pCR) [42,43]. Indeed, the
US Food and Drug Administration has stated that pCR may be used
as a surrogate endpoint to support accelerated approval for neo-
adjuvant treatment of early breast cancer, and its use is also under
discussion by the European Medicines Agency [44,45]. Ki-67 drop
under neoadjuvant endocrine therapy is a possible surrogate
endpoint for longer disease-free survival for individuals with ERþ
tumors.
Future efforts in drug development in breast cancer are likely to
focus on implementing molecular screening and next-generation
sequencing (NGS) into drug development [46]. The knowledge
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take many years before the therapeutic hypotheses developed from
this vast data repository will be addressed. Nonetheless, a new
treatment paradigm is evolving whereby deep genomic analysis
will drive treatment decisions based on a pharmacopoeia of cell
type and pathway-matched therapies. However, funding for pivotal
phase III clinical trials for novel agents targeting rare mutations is
an important concern since such agents may only beneﬁt small
numbers of patients, presenting a considerable economic challenge
for drug development. Over the past few decades, National Cancer
Institute (NCI) Clinical Trials Co-operative Groups, charities and
government-initiated research councils have played a key role in
the funding and organization of clinical trials in oncology. However,
in the current economic climate, government and public funding
for such trials has progressively decreased. Furthermore, recruit-
ment of patients with speciﬁc molecular aberrations into trials will
be challenging given the relatively low frequency of the wide range
of alterations. Indeed, trials involving patients with rare mutations
may be more suited to international collaboration due to the
numbers of patients required for screening. As a result, future trials
are likely to require interactions between co-operative groups,
academia, industry and networks of institutions involved in mo-
lecular screening (e.g. the Breast International Group [BIG] pro-
gram) [47] to increase the likelihood of success.
In the last two decades, most of the academic research efforts
have focused on early-stage disease. However, recently there is
growing interest in metastatic disease with the hope of eradicating
existing metastases [48], preventing tumor-cell dissemination
[49,50] or reducing the ability of disseminated cells from adapting
to the novel microenvironment at distant sites [51,52]. Additional
changes to drug development in the future may involve strategies
to target multiple signaling pathways in order to minimize resis-
tance and improve efﬁcacy, and the development of pharmacody-
namic endpoints (e.g. imaging, ctDNA, circulating tumor cells
[CTCs]) to assess the activity of targeted agents andmonitor disease
progression [53,54]. CTC detection has already been shown to be an
early marker for disease progression with prognostic relevance
after the start of treatment for metastatic disease [55e57]. Further
ongoing trials (e.g. SWOG 0500 and NCT01185509) should clarify
the role of CTCs in the management of patients with breast cancer
and conﬁrm its utility for both monitoring the efﬁcacy of treatment
and as a predictive tool. ctDNA, analyzed by multiplex tumor mu-
tation sequencing, has also been shown to be a non-invasive means
of monitoring disease progression, with higher concentrations
being correlated with worse OS [58,59]. Assessment of such
circulating blood biomarkers holds great promise for the future,
though their routine incorporation into clinical trials will require
the development of robust standardized assays.
Biomarkers of response or resistance are also required to
enhance treatment efﬁcacy and reduce costs; their identiﬁcation is
likely to play a major role in any further advances in breast cancer
management. Since the impact of different mutation drivers may
vary according to stage, biomarker research must investigate mu-
tations in both the primary tumor and metastases. Care is also
needed to ensure that biomarker trial designs are appropriate and
have sufﬁcient power; with the increasing fragmentation of breast
cancer into small molecular subsets, there is a need for collabora-
tion within large networks.
Resistance to targeted agents and the challenge of intra-
tumor heterogeneity
Inter- and intra-tumor heterogeneity in breast cancer and other
solid tumors has signiﬁcant implications for both therapeutics and
biomarker discovery, presenting a signiﬁcant barrier to improvingsurvival outcomes [60]. Discordance in ER, PgR and HER2 receptor
status between primary and metastatic breast cancer has beenwell
reported [61,62], yet therapeutic decisions for patients with met-
astatic disease are frequently based on the features of the primary
tumor. Biopsies of breast cancer metastases can help to individu-
alize therapy based on the proﬁle of the metastatic disease; how-
ever, clinical and genomic heterogeneity also exists across
metastases and tumors continually evolve over time [63]. Molec-
ular screening programs such as that undertaken by the BIG aim to
perform large-scale screening and sequencing of metastatic breast
cancer patients with an effort at understanding better the clonal
evolution of the disease. The results of these platforms will assist in
determining the optimal treatment for patients with metastatic
disease in the future. Until this time, biopsy of the ﬁrst metastasis to
conﬁrm metastatic disease and hormone status prior to treatment
selection is recommended by most guidelines [31].
Resistance to systemic therapies is an additional obstacle
[64e66]. Many patients with metastatic breast cancer present with
intrinsic endocrine resistance, and all patients develop acquired
resistance to multiple agents over time [67]. Evidence is emerging
that low-frequency subclones may determine outcome, raising
challenges to biomarker approaches in oncology. For example, low-
frequency presence (~1%) of the EGFR T790M mutation, which
confers resistance to EGFR tyrosine kinase inhibitors, leads to
poorer progression-free survival (PFS) outcomes following EGFR
targeted therapy in non-small cell lung cancer. However, current
biomarkers are often not directed at the detection of such low-
frequency genetic events, underlining the need for improved
methods of detection that will better predict outcome following
therapy. Genetic events present early in the evolution of the tumor
(e.g. those found in the trunk of the tumor's phylogenetic tree) may
present optimal biomarkers and therapeutic targets [68]. A further
issue is the fact that several signaling pathways have been associ-
ated with the development of endocrine resistance, including the
PI3K/AKT/mTOR (phosphatidylinositol 3-kinase/serine/threonine
kinase/mammalian target of rapamycin), CDK 4e6 (cyclin-depen-
dent kinase 4e6)/cyclin D1 E2F and AP-1 pathways [69e71],
complicating the development of new agents.
A number of strategies may be exploited in the future to either
manage or impede resistance to targeted therapy as described
below. For example, cross-talk exists between ER and growth factor
receptor signaling, with hyperactivation of the PI3K pathway (a
frequently mutated pathway in breast cancer) being shown to
promote resistance to endocrine therapy (Fig. 1) [70]. The BOLERO-
2 trial has demonstrated the effectiveness of targeting this
pathway, given the 6-month gain in PFS seen when an mTOR in-
hibitor (everolimus) was added to exemestane in patients in whom
a non-steroidal AI had failed [72]. Moreover, a number of PI3K in-
hibitors are currently in development, and the possibility of
combining these agents with endocrine therapy is being investi-
gated as a therapeutic strategy for patients developing resistance to
hormonal agents.
Another promising therapeutic strategy for luminal breast
cancer treatment is inhibition of CDK 4e6, as shown in several
preclinical studies [71,73] and recent data from a phase II trial of the
CDK 4e6 inhibitor palbociclib (PD-0332991) used in combination
with letrozole as ﬁrst-line treatment [74]. Results of preclinical
studies also suggest that resistance to endocrine treatment is
associated with oxidative stress and elevated AP-1 activity, and that
AP-1 levels are higher in tamoxifen-resistant tumors [75,76].
Although further validation is needed, this indicates that blockade
of AP-1 function may well reverse tamoxifen resistance. A further
approach that may affect the development of resistance is
sequencing or intermittent use of endocrine therapy. This strategy
has shown promise in a xenograft study employing intermittent
Fig. 1. Cross-talk between estrogen receptor (ER) and growth factor receptor signaling pathways. Reproduced with permission from Miller et al., 2011 [70]. Receptor tyrosine
kinases (RTKs) and G-protein-coupled receptors activate phosphatidylinositol 3-kinase (PI3K; blue) and MAPK/Erk (MEK) signaling pathways. These signal transducers then
phosphorylate ER (green arrow) and/or coactivators and corepressors to modulate ER transcriptional activity not necessarily dependent on ER ligands. In turn, ER transcribes genes
encoding components of growth factor signaling pathways, thus completing the signaling cycle of RTKs to ER to RTKs. ER also complexes with RTKs and Src to rapidly induce
nongenomic signaling. ER-interacting proteins are shown in color. AIB1, ampliﬁed in breast cancer 1; EGFR, epidermal growth factor receptor; GSK-3, glycogen synthase kinase-3;
IGF-1R, insulin-like growth factor-1 receptor; IGFBP, insulin-like growth factor binding protein; IRS-1, insulin receptor substrate 1; JNK, c-Jun N-terminal kinase; MAP, mitogen-
activated protein kinases; PI3K, phosphatidylinositol 3-kinase; PTEN, phosphatase and tensin homolog; RTK, receptor tyrosine kinase; SGK3, serum/glucocorticoid-regulated ki-
nase-3; Stat5b, signal transducer and activator of transcription 5b; TGFa, transforming growth factor alpha; TORC1, target of rapamycin complex 1. (For interpretation of the
references to color in this ﬁgure legend, the reader is referred to the web version of this article.)
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phase III trial of continuous versus intermittent letrozole in patients
with ERþ/nodeþ breast cancer who are disease free after 5 years of
adjuvant endocrine therapy.New therapeutic targets for drug treatment in breast cancer
Agents directed at intra-tumoral targets
A number of new potential intra-tumoral targets have been
identiﬁed in breast cancer, including tyrosine kinases, ﬁbroblast
growth factor (FGF) signaling, insulin-like growth factor, hepato-
cyte growth factor and c-MET (Table 2) [78]. Ampliﬁcation of one of
these targets, FGF receptor 1, is seen in around 10% of breast can-
cers, with increased expression correlating with poor prognosis
and conferring tamoxifen resistance [79]. Expression of c-MET also
correlates with poor prognosis and is seen in all breast cancer
subtypes [80]. Further novel targets include second messengers
such as PI3 kinase mutation, phosphatase and tensin homolog
(PTEN) loss, rare mutations including AKT, PTEN and Janus kinase
(JAK), DNA repair alterations and modulation of the p53 pathway.
Interruption of DNA repair has been investigated as a strategy for
enhancing the activity of chemotherapy in a number of cancers,
with efforts focusing on the use of poly(ADP-ribose) polymerase
(PARP) inhibitors in DNA repair-deﬁcient cancer [81]. In breast
cancer, PARP inhibitors are being investigated as a monotherapy for
the treatment of patients with BRCA1/BRCA2 mutations [82] and
those with TNBC. While monotherapy with PARP inhibitors is
generally well tolerated, a potential but as yet unknown risk of
mutation induction and second cancer induction must be consid-
ered with chronic inhibition of PARP, given its roles in DNA repair.
Although identiﬁcation of new intra-tumoral targets is an area
of active research in breast cancer, drug development requires
improved understanding of tumor biology and biomarkers ofoutcome, using preclinical studies such as those employing mouse
xenografts to identify the molecular proﬁles likely to respond [83].
Patient-derived breast tumor xenografts (PDXs) are also likely to
play a key role in improving our understanding of the complexity
and molecular heterogeneity of breast cancer since they retain the
morphology, heterogeneity and molecular proﬁles of the original
tumor [84]. Although not all intrinsic breast cancer subtypes are
currently represented in PDX models, their use holds particular
promise for screening therapeutic agents prior to clinical trials,
which is likely to greatly assist the development of future person-
alized cancer therapy.
There are also challenges associated with the integration of
novel agents into current breast cancer management, including
optimal scheduling and combination with cytotoxics, though
pharmacodynamic parameters can be helpful in this regard. In
particular, studies suggest that the optimal biologic dose of the
agent should be identiﬁed rather than themaximum tolerated dose
[85]. Continuous low-dose administration of chemotherapy may
also be more effective than intermittent high doses [86], the
concept of cyclotherapy has been proposed [87] and the combi-
nation of new targeted agents withmetronomic chemotherapy also
merits exploration.Agents targeting the tumor stromal compartment
Immunotherapy is thought to be the future direction for biologic
therapy in breast cancer as a strategy to target diversity, and novel
therapies are expected to control tumor growth without the side
effects of traditional treatments. Current research efforts are
focusing on a number of immune targets that could be exploited in
breast cancer, using antibodies or vaccines to augment the innate
immune response against cancer cells. For example, antibody
therapy can be used to target the priming or effector phase re-
sponses to the antigen of the tumor, through blockade of proteins
Table 2
Selected new targets for drug treatment in breast cancer and novel agents in development.
Molecular target Agents in development Company Development phase
Intra-tumoral targeted agents
Transmembrane tyrosine kinases
IGF Cixutumumab ImClone Systems Inc. I/II
MEDI-573 MedImmune I/II
BMS-754807 Bristol-Myers Squibb I
HGF Ficlatuzumab AVEO II
Rilotumumab Amgen II
TAK-701 Millennium Pharmaceuticals I
cMET Onartuzumab (OA5D5) Genentech II
LY-2875358 Eli Lilly II
Tivantinib (ARQ-197) Daiichi Sankyo II/III
Foretinib (XL-880) Elexis II
Secondary messengers
P13K/AKT/mTOR XL147 Exelixis/Sanoﬁ-Aventis I
BYL719 Novartis I
BKM120 Novartis I
GDC-0032 Genentech I
DNA repair alterations
PARP Rucaparib Clovis II
Olaparib AstraZeneca II
Veliparib Abbott II
MK-4827 Merck I
CEP-9722 Cephalon I
BMN673 Biomarin I
E7016 Eisai I
Others
AR Enzalutamide Medivation/Astellas II
Abiraterone Janssen II
Hsp90 NVP-AUY922 Novartis II
Ganestespib Synta III
CDK PD0332991 Pﬁzer II
Extracellular compartment targeted agents
Angiogenic vascular cells
VEGF Tivozanib AVEO/Astellas I/II
Sunitinib Pﬁzer III
Sorafenib Bayer III
Ramucirumab Eli Lilly/Imclone III
Inﬁltrating immune cells
PD-1/PD-L1 MDX-1105-01 Bristol-Myers Squibb I
AMP-514 MedImmune I
MPDL3280A Genentech I
CTL Ipilimumab (MDX-010) Yervoy II
TAM PLX3397 Plexxikon I/II
Cancer-associated ﬁbroblastic cells
MMP Tanomastat (BAY 12-9566) Bayer I
TRAIL Tigatuzumab Daiichi Sankyo I
PRO95780 Genentech I
AR, androgen receptor; CDK, cyclin-dependent kinase; CTL, cytotoxic T-lymphocytes; HGF, hepatocyte growth factor; Hsp90, heat shock protein 90; IGF, insulin-like growth
factor; MMP, matrix metalloproteinase; PARP, poly(ADP-ribose) polymerase; P13K/AKT/mTOR, phosphatidylinositol 3-kinase/serine/threonine kinase/mammalian target of
rapamycin; TAM, tumor-associated macrophages; TRAIL, tumor necrosis factor-related apoptosis-inducing ligand; VEGF, vascular endothelial growth factor.
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[CTLA-4] and programmed death 1 [PD-1], respectively) [88,89].
Additional novel agents in development that target the non-
malignant tumor stroma include trabectedin, which inhibits
macrophage differentiation, receptor activator of nuclear factor k B
(RANK) ligand inhibitors (e.g. denosumab) and drugs targeting the
tumor necrosis factor-related apoptosis inducing ligand (TRAIL)
pathway (e.g. mapatumumab, dulanermin) [90e93]. Matrix met-
alloproteinase (MMP)-targeted agents are also under investigation
(e.g. marimastat, prinomastat) since MMPs are up-regulated in
malignant tissues [94,95]; however, it should be noted that all
MMP-targeted agents produced to date have failed in clinical
development [96].
The development of immunotherapeutic agents should focus
on the use of immunomodulators, alone or in combination with
low-dose cytotoxics, to decrease the immunosuppression
induced by T-cell effector up-regulation. TNBC and HER2þ breast
cancer may be useful settings for the initial study ofimmunotherapy, as these tumor subtypes have shown higher
levels of immune inﬁltration compared with luminal BC [97e99].
Combination of an anti-HER2 drug with the novel immuno-
therapy agent should be considered in this population. It should
be noted, however, that TNBCs are highly heterogeneous and
may be classiﬁed into seven different subtypes by gene expres-
sion microarray [100]. Differential responses have already been
reported among these molecular subtypes [101], and it may be
anticipated that their responses to immune stimulation could
also differ.
Breast cancer medicine is increasingly moving towards a new
era of personalized therapeutics, with strategies targeting cancer
cell intrinsic and extrinsic pathways as well as mediators of the
tumor microenvironment. The importance of the microenviron-
ment and its potential in cancer therapy is just being established.
Among modalities that target the microenvironment, the har-
nessing of immune responses has long been pursued, though ef-
forts must avoid immune over-activation. Nevertheless, blockade of
A. Di Leo et al. / The Breast 24 (2015) 321e330 327immune cell-intrinsic checkpoints, such as CTLA-4 or the PD-1 re-
ceptor, has provided the ﬁrst evidence of activity of an immune-
modulation approach in the treatment of a solid tumor and
further advances in this ﬁeld are expected.
Summary
The advent of targeted therapy has led to considerable progress
in the treatment of breast cancer in recent years, though challenges
remain, including the currently inadequate classiﬁcation of breast
cancer subtypes. Improved understanding of the molecular pa-
thology of breast cancer has resulted in the identiﬁcation of new
targets for drug treatment and evolving classiﬁcations should
reﬂect these developments. Further ongoing issues include resis-
tance to systemic therapy, the high cost of drug treatment and the
slow progress made in reducing rates of metastatic disease. How-
ever, Table 3 provides a detailed vision for improvement, suggest-
ing a number of strategies designed to address these problems.
Adoption of some of these approaches may be expected to lead toTable 3
Challenges in breast cancer and proposals for addressing them.
Challenge Prop
Treatment selection relies on accurate determination of hormone
and HER2 receptor status, yet measurement varies considerably
between centers
 St
ac
No single treatment algorithm can be deﬁned for patients with
advanced disease as many factors have an impact on
treatment decisions
 Tr
bo
 Fa
re
bio
an
 Cl
m
se
Dual targeting interventions for patients with HER2þ breast cancer are
expensive and ways of identifying the subpopulation that will beneﬁt
from such treatment are needed
 Us
se
Although advances have been made in the treatment of early
breast cancer, little progress has been seen in reducing rates
of metastatic disease
 Im
in
 De
(e
Development of new drugs for breast cancer is limited by high cost,
poor success rates and lack of understanding of the subpopulations
that would beneﬁt
 Id
th
 No


 In
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ne
 Ta
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th
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pr
Use of OS as a mandatory endpoint for advanced breast cancer
registration trials may limit new ﬁrst- or second-line options
for patients with metastatic disease
 Us
or
Many patients with metastatic breast cancer present with intrinsic
endocrine resistance and all patients develop acquired resistance
to multiple agents over time
 St



Integration of novel agents into current management is challenging,
and optimal scheduling and combination with cytotoxics has not
been determined
 Id
 St
ad
m
ctDNA, circulating tumor DNA; CTCs, circulating tumor cells; ER, estrogen receptor; HER
tolerated dose; NGS, next-generation sequencing; OS, overall survival; pCR, pathologic c
rapamycin.further improvements in both treatment and outcomes for patients
with breast cancer.
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